AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06502626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
Study NCT05484336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage containing 8g spirulina
Description: Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT05278611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-9001A
Description: The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
Study NCT05278611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05153252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Exercise
Description: Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
Study NCT05153252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening Exercise
Description: PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
Study NCT04343027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Review
Description: Physicians will review patient-reported outcome measurements with their patients during office visits.
Study NCT03718650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Description: Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
Study NCT03718650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
Study NCT06421298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafolecimab
Description: 450mg Q4W ≤6cycle
Study NCT06421298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg Q3W ≤2years
Study NCT06421298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 130mg/m² Q3W 4-6cycles
Study NCT06421298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² Q3W 4-6cycles
Study NCT06421298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m² Q3W 4-6cycles
Study NCT06381557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhengyuan Capsules
Description: Zhengyuan capsules, 4 capsules at a time, 3 times per day;
Study NCT06381557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo contains 5%-10% Zhengyuan Capsule total mixed powder
Description: Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
Study NCT06197464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation on emotional regulation and distraction strategy
Description: The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
Study NCT06197464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using the FLOAT app on a virtual reality device
Description: The subject should wear the VR device, and use the FLOAT application.
Study NCT06197464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation on emotional regulation and distraction strategy + Application
Description: psychoeducation on emotional regulation and distraction strategy + Application
Study NCT04911764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Three-min Step Test and Exercise desaturation detection in COPD
Description: For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
Study NCT05545202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pentaisomaltose
Description: Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
Study NCT05545202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentaisomaltose
Description: Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
Study NCT04167215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior gluteal artery flap and lumbar artery falp
Description: Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
Study NCT04167215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The gluteal pocket
Description: pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
Study NCT04167215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: infragluteal dermal lifiting flap
Description: dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
Study NCT04095689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Microtubule-targeting drug (inhibits microtubule depolymerization)
Study NCT04095689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Programmed cell death-1 (PD-1) inhibitor
Study NCT04095689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-12 gene therapy
Description: Adenoviral-mediated IL-12
Study NCT04904809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System
Description: The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
Study NCT05157347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted Training
Description: The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
Study NCT05157347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
Study NCT05505188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report
Study NCT05513313 — intervention group
Intervention type: BIOLOGICAL
Intervention: JYNNEOS
Description: smallpox vaccine
Study NCT05835921 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality
Description: Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
Study NCT05835921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
Study NCT06258655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Close Collaboration with Parents
Description: The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation.
Study NCT06350292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP: COPE
Description: Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
Study NCT05236985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin bolus or oxytocin infusion
Description: On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded.
Study NCT04460586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Injection [Nuzyra]
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Study NCT04460586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Oral Tablet [Nuzyra]
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Study NCT05118815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slim abutment
Description: Use a narrower abutment to see if they present a better biological seal.
Study NCT05118815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard abutment
Description: Use a standard abutment
Study NCT04940650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: exercise testing
Description: To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
Study NCT04940650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
Study NCT06486688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centralized Virtual SBIRT
Description: Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
Study NCT06486688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Centralized Virtual SBIRT
Description: Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
Study NCT06169800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPFL repair with Biobrace augmentation
Description: MPFL repair with Biobrace augmentation
Study NCT05589207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular wall invaded
Description: Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
Study NCT04973345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: management of asthma symptoms
Study NCT05750433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreforPro+B. subtilis DE111 probiotics
Description: PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
Study NCT05750433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin is rice based powder which was used as placebo.
Study NCT05750433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. subtilis DE111
Description: Bacillus subtilis probiotics.
Study NCT04983797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTRELL Mapping Catheter
Description: Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
Study NCT04226976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study NCT04226976 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study NCT04784312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection
Description: 9MW1411 injection
Study NCT04784312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 9MW1411 injection placebo
Description: 9MW1411 injection placebo
Study NCT05418192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Environment
Description: Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
Study NCT05418192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Physcial Therapy
Description: Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
Study NCT05387733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg CBL-514 per injection
Description: The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514.
Study NCT05387733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg CBL-514 per injection
Description: The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of >2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of >3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of >5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514.
Study NCT06297109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-specific implants
Description: Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
Study NCT06297109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mini-plates
Description: Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
Study NCT06151795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: XTR006
Description: Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
Study NCT05837429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Volume High Intensity Exercise Training
Description: Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
Study NCT05837429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
Study NCT05934929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA detection
Description: biological assessment on operating bed to detect residual circulating tumor DNA
Study NCT01154361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant (subcutaneous) and plazebo (intravenous)
Study NCT01154361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)
Study NCT04533997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution plus intravenous furosemide
Description: Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide > 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%
Study NCT04533997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous furosemide
Description: Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide > 160 mg
Study NCT04726176 — intervention group
Intervention type: BIOLOGICAL
Intervention: Exposure to COVID-19
Description: To study the exposure of COVID-19 on the brain and executive functioning
Study NCT04738344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention and Stent Implantation
Description: Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
Study NCT05755971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combination taping
Description: Elastic and rigid tapes applied together for six weeks